Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Arrhythmogenic cardiomyopathy (ACM) is an inheritable heart muscle disease characterised pathologically by fibrofatty myocardial replacement and clinically by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). Although, in its original description, the disease was believed to predominantly involve the right ventricle, biventricular and left-dominant variants, in which the myocardial lesions affect in parallel or even mostly the left ventricle, are nowadays commonly observed. The clinical management of these patients has two main purposes: the prevention of SCD and the control of arrhythmic and heart failure (HF) events. An implantable cardioverter defibrillator (ICD) is the only proven lifesaving treatment, despite significant morbidity because of device-related complications and inappropriate shocks. Selection of patients who can benefit the most from ICD therapy is one of the most challenging issues in clinical practice. Risk stratification in ACM patients is mostly based on arrhythmic burden and ventricular dysfunction severity, although other clinical features resulting from electrocardiogram and imaging modalities such as cardiac magnetic resonance may have a role. Medical therapy is crucial for treatment of VAs and the prevention of negative ventricular remodelling. In this regard, the efficacy of novel anti-HF molecules and drugs acting on the inflammatory pathway in patients with ACM is, to date, unknown. Catheter ablation represents an effective strategy to treat ventricular tachycardia relapses and recurrent ICD shocks. The present review will address the current strategies for prevention of SCD and treatment of VAs and HF in patients with ACM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
Arrhythmogenic Right Ventricular Cardiomyopathy: Dysplasia, Dystrophy, or Myocarditis?
Basso, C., Thiene, G., Corrado, D., Angelini, A., Nava, A., & Valente, M. (1996) · Circulation · doi:10.1161/01.cir.94.5.983 · Cited by 890
Self-citationGarcia-Gras, E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27751 · Cited by 623
Corrado, D., van Tintelen, P. J., McKenna, W. J., Hauer, R. N. W., Anastastakis, A., Asimaki, A., Basso, C., Bauce, B., Brunckhorst, C., Bucciarelli-Ducci, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz669 · Cited by 366
Self-citationAsimaki, A., Kapoor, S., Plovie, E., Karin Arndt, A., Adams, E., Liu, Z., James, C. A., Judge, D. P., Calkins, H., Churko, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008008 · Cited by 274 · cited 4×
“NFκB promotes inflammatory responses and interacts with GSK3β.”
BackgroundInfluentialPilichou, K., Remme, C. A., Basso, C., Campian, M. E., Rizzo, S., Barnett, P., Scicluna, B. P., Bauce, B., van den Hoff, M. J. B., de Bakker, J. M. T., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090641 · Cited by 210
Self-citationTherapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy
Chelko, S. P., Asimaki, A., Lowenthal, J., Bueno-Beti, C., Bedja, D., Scalco, A., Amat-Alarcon, N., Andersen, P., Judge, D. P., Tung, L., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040676 · Cited by 192
Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy
Chelko, S. P., Asimaki, A., Andersen, P., Bedja, D., Amat-Alarcon, N., DeMazumder, D., Jasti, R., MacRae, C. A., Leber, R., Kleber, A. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85923 · Cited by 180
Chatterjee, D., Fatah, M., Akdis, D., Spears, D. A., Koopmann, T. T., Mittal, K., Rafiq, M. A., Cattanach, B. M., Zhao, Q., Healey, J. S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy567 · Cited by 161 · cited 1×
“The presence of autoantibodies has been reported in ACM patients and in their relatives, with a positive status being more frequent in a familial than in a sporadic pattern [35,36].”
Background‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy
Bariani, R., Cipriani, A., Rizzo, S., Celeghin, R., Bueno Marinas, M., Giorgi, B., De Gaspari, M., Rigato, I., Leoni, L., Zorzi, A., et al. (2021) · EP Europace · doi:10.1093/europace/euaa343 · Cited by 154
Self-citation
Cited by
Cicenia, M., & Drago, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040098 · Cited by 21
“Heart failure (HF) is another complication occurring in the advanced stages of the disease and it requires treatment with traditional pharmacological therapies or advanced mechanical support and heart transplant (HT) [15].”
BackgroundArrhythmogenic Cardiomyopathy or “Athlete’s Heart”?
Minopoli, T. C., Kanthagnani, K., Olivotto, I., Sharma, R., Papadakis, M., Sharma, S., & Finocchiaro, G. (2025) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.08.026 · Cited by 6
Saha, D., Dutta, P., & Chakraborty, A. (2025) · Immuno · doi:10.3390/immuno5040045 · Cited by 3
Sommariva, E., Lippi, M., Bruttini, F., Cannata, F., Baggiano, A., Schiavone, M., Salina, G., Sabatino, M., Vettor, G., Sicuso, R., et al. (2025) · PLOS One · doi:10.1371/journal.pone.0332876 · Cited by 3
Metadata
- Authors
- Migliore, F., Mattesi, G., Zorzi, A., Bauce, B., Rigato, I., Corrado, D., & Cipriani, A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-22
- Volume
- 10
- Issue
- 13
- Pages
- 2750
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3174655525
- Cited by
- 29
- References
- 11
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options. https://app.cochat.ai/papers/10.3390/jcm10132750
- The paper
- Migliore, F., Mattesi, G., Zorzi, A., Bauce, B., Rigato, I., Corrado, D., & Cipriani, A. (2021). Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10132750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.